The Malaghan Institute of Medical Research in collaboration with Wellington Zhaotai Therapies Limited today announced results of its phase 1 dose escalation trial of a new third generation anti-CD19 ...

ATA3219 Demonstrates Complete CD19-Specific B-Cell Depletion Against Systemic Lupus Erythematosus and Multiple Sclerosis Patient Peripheral Blood Mononuclear Cells ATA3219 Induces Lower Levels of ...

Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown remarkable clinical efficacy in B-cell cancers. However, CAR T cells can induce substantial toxic effects, and the manufacture of the ...

Please provide your email address to receive an email when new articles are posted on . Most patients with B-cell lymphomas who relapsed after CAR T-cell therapy responded to the novel, ...

Chimeric antigen receptor T (CAR-T) cell therapy has emerged as a transformative approach in modern medicine, demonstrating remarkable efficacy in targeting pathogenic B-cell lineages with ...

A phase 1 trial of a human thymus-expressed apoptosis factor in patients with advanced solid tumors: Interim report. This is an ASCO Meeting Abstract from the 2015 ASCO Annual Meeting I. This abstract ...

The CD19 inhibitors market is projected to expand substantially in the coming years. This growth is driven by a rising number of patients diagnosed with conditions such as NHL, ALL, NMOSD, IgG4-RD ...

Please provide your email address to receive an email when new articles are posted on . Although chimeric antigen receptor T-cell therapy has delivered previously unthinkable remission outcomes to ...

Antengene Corporation Limited (Antengene), a leading innovative, commercial-stage global biotech company, and UCB, a global ...